Purpose

This research study, funded by the National Institute of Aging, uses risperidone (an FDA-approved antipsychotic medication) to treat people with Alzheimer's disease who suffer from hallucinations, delusions, agitation, and/or aggression. Treatment continues over a period of 48 weeks. Each eligible participant must have a family member or caregiver who can assist with adherence to treatment and provide information during the research study.

Type of Study: Clinical Trial
Setting of Study: outpatient
Clinical Trials.gov number: 
Providing Clinical Treatment?: Yes
No Cost Treatment?: Yes

Study Activities

Blood Samples
Blood Samples for DNA
Provides Payment: Reimbursement for transportation
Provides Payment: Compensation for study related procedures

Eligibility

Ages Eligible for Study: 40 Years - 95 Years
Genders Eligible for Study: Both
This study is not recruiting Healthy Volunteers.

Criteria

Location: 
Clinic: Memory Disorders Clinic
Division: Biological Psychiatry

Study chairs or principal investigators:
D.P. Devanand M.D., Principal Investigator

Co-investigators:
Gregory Pelton,
Bruce Levin,